| Clinical Neurology | Lifetime | 92 | JP 2 | 99.68 |
| Cellular and Molecular Neuroscience | Lifetime | 331 | JP 5 | 98.82 |
| Pathology and Forensic Medicine | Lifetime | 622 | JP 13 | 97.19 |
| Neuroscience of Neurology | Lifetime | 770 | JP 32 | 92.72 |
| Medical Genetics | Lifetime | 748 | JP 15 | 91.37 |
| Clinical Neurology | 2021-2025 | 47 | JP 2 | 99.03 |
| Cellular and Molecular Neuroscience | 2021-2025 | 75 | JP 2 | 94.37 |
| Pathology and Forensic Medicine | 2021-2025 | 295 | JP 7 | 90.71 |
| Peripheral Nerve Disorders | Lifetime | 12 | JP 1 | 99.62 |
| Hereditary Neurological Disorders | Lifetime | 9 | JP 1 | 99.51 |
| Myasthenia Gravis and Thymoma | Lifetime | 18 | JP 1 | 99.39 |
| Peripheral Neuropathies and Disorders | Lifetime | 26 | JP 1 | 99.63 |
| Nerve injury and regeneration | Lifetime | 126 | JP 3 | 99.03 |
| Neurogenetic and Muscular Disorders Research | Lifetime | 96 | JP 4 | 98.85 |
| Autoimmune Neurological Disorders and Treatments | Lifetime | 34 | JP 1 | 98.50 |
| Long-Term Effects of COVID-19 | Lifetime | 343 | JP 3 | 97.20 |
| Amyotrophic Lateral Sclerosis Research | Lifetime | 128 | JP 6 | 98.27 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 642 | JP 27 | 97.98 |
| Botulinum Toxin and Related Neurological Disorders | Lifetime | 455 | JP 7 | 97.57 |
| Pain Mechanisms and Treatments | Lifetime | 658 | JP 24 | 97.33 |
| Multiple Sclerosis Research Studies | Lifetime | 408 | JP 8 | 97.54 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 160 | JP 8 | 93.09 |
| Neurological and metabolic disorders | Lifetime | 617 | JP 41 | 90.51 |
| Infectious Encephalopathies and Encephalitis | Lifetime | 859 | JP 108 | 82.36 |
| Pathogenesis and Treatment of Hiccups | Lifetime | 941 | JP 128 | 47.81 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 19 | JP 1 | 99.06 |
| Hereditary Neurological Disorders | 2021-2025 | 7 | JP 1 | 97.79 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 18 | JP 3 | 98.41 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 968 | JP 27 | 90.35 |
| Amyotrophic Lateral Sclerosis Research | 2021-2025 | 348 | JP 17 | 87.98 |
| Antifungal resistance and susceptibility | 2021-2025 | 583 | JP 20 | 89.45 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 582 | JP 30 | 85.38 |
| Neurogenetic and Muscular Disorders Research | 2021-2025 | 571 | JP 27 | 84.32 |
| Multiple Sclerosis Research Studies | 2021-2025 | 860 | JP 13 | 87.90 |
| Autoimmune Neurological Disorders and Treatments | 2021-2025 | 230 | JP 8 | 83.95 |
| Peripheral Nerve Disorders | 2021-2025 | 272 | JP 8 | 81.24 |
| Infectious Encephalopathies and Encephalitis | 2021-2025 | 148 | JP 30 | 75.21 |
| Parkinson's Disease and Spinal Disorders | 2021-2025 | 104 | JP 13 | 77.49 |
| Protein Tyrosine Phosphatases | 2021-2025 | 214 | JP 6 | 72.46 |
| Neurological and metabolic disorders | 2021-2025 | 356 | JP 30 | 61.47 |
| Chemotherapy-related skin toxicity | 2021-2025 | 323 | JP 13 | 60.04 |
| Alcoholism and Thiamine Deficiency | 2021-2025 | 278 | JP 16 | 59.03 |
